Safi R. Bahcall, Ph.D.
|
Director, President and Chief Executive Officer
|
Dr. Bahcall co-founded Synta with Dr. Lan Bo Chen and has been Chief Executive Officer and a member of the board of directors since July 2001, and President since December 2003. Dr. Bahcall has led Synta from inception through multiple acquisitions, financings, an initial public offering, and the establishment of integrated, multi-product drug discovery and development organization. Prior to founding Synta, Dr. Bahcall was a consultant at McKinsey & Company advising investment banks and pharmaceutical companies on strategy, technology, and operations. Dr. Bahcall also co-founded a drug discovery company focused on novel ion channel research, now part of Synta. Dr. Bahcall received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral fellow at U.C. Berkeley. In 2008, Dr. Bahcall was named Ernst & Young New England Biotechnology/Pharmaceutical Entrepreneur of the Year.
|
|
Michael P. Bailey, MBA
|
Senior Vice President Business Development and Chief Commercial Officer
|
Before joining Synta in August 2008, Mr. Bailey led ImClone's Worldwide Commercial Organization, responsible for commercial aspects for the planning and launch of Erbitux(R) across multiple indications. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and Worldwide partnerships. Prior to joining ImClone, Mr. Bailey served at Genentech, Inc. where he managed the company's cardiovascular development portfolio. Mr. Bailey started his career in the pharmaceutical industry as one of two MBA graduates selected for Smith-Kline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey earned a B.S. in Psychology from St. Lawrence University and holds an M.B.A. in International Marketing from the University of Notre Dame Graduate School of Business.
|
|
Jeremy G. Chadwick, Ph.D.
|
Senior Vice President, Program Management and Clinical Operations
|
Before joining Synta in May 2004, Dr. Chadwick served as Vice President Development Operations at Vertex Pharmaceuticals. During his tenure at Vertex, Dr. Chadwick's responsibilities included outsourcing, planning, new systems and technologies, portfolio management, drug safety, medical writing and clinical pharmacology. Prior to joining Vertex, Dr. Chadwick held various positions including Vice President, US Biostatistics and Data Management at Parexel International; Senior Manager, Medical Data Sciences Division, Glaxo Group Research; and Chief Operating Officer at Foliage Software Systems, a privately-held high-end software development company. Dr. Chadwick obtained both his Masters and Ph.D. in statistics from the University of London, UK.
|
|
Keizo Koya, Ph.D.
|
Senior Vice President, Drug Development
|
Dr. Koya led the research and development of numerous investigational cancer and autoimmune drugs as the VP, R&D at Shionogi BioResearch. A synthetic chemist by training, Dr. Koya was the Director, Drug Discovery and Development at Fuji ImmunoPharmaceuticals, and the Head of Pharmaceutical R&D at Fuji Photo. He also was involved in the development of MKT-077, the first mitochondria-based anticancer agent. Dr. Koya has more than 34 issued and pending U.S. patents. Dr. Koya earned his Ph.D. in organic chemistry at Kyushu University.
|
|
Vojo Vukovic, M.D., Ph.D.
|
Senior Vice President, Chief Medical Officer
|
Dr. Vukovic joined Synta as Vice President, Clinical Research in January 2009. Dr. Vukovic has over 17 years experience in oncology drug development. Prior to Synta, he was Global Medical Lead for Sutent® and axitinib in a number of cancer indications at Pfizer. Prior to Pfizer, he served in key medical and regulatory roles at Aventis Pasteur, Ortho Biotech, ILEX Oncology, and BioNumerik Pharmaceuticals. Over the course of his career, Dr. Vukovic has been responsible for over 100 Phase 1 to Phase 4 clinical studies in cancer indications including melanoma, tumors of the lung, pancreas, breast, colorectal, ovarian, brain, as well as NHL and certain leukemias. Prior to his industry career, Dr. Vukovic was a post-doctoral fellow at the Ontario Cancer Institute, Toronto in Ontario and Institute for Cell Biology in Essen, Germany where he conducted basic and translational research in solid tumor microenvironments and oxidative stress. Dr. Vukovic received his Ph.D. and M.Sc. degrees from the University of Toronto and his M.D. degree from the University of Sarajevo, Bosnia and Herzegovina.
|
|
Suresh R. Babu, Ph.D.
|
Vice President, Drug Product Development
|
Before joining Synta in January 2006, Dr. Babu was employed at Pfizer Global R&D with responsibility for discovery formulation, preformulation, and formulation development. Prior to Pfizer, Dr. Babu worked for Johnson & Johnson identifying and implementing new technologies for drug delivery. Dr. Babu has extensive pharmaceutical industry experience in the areas of preformulation, enabling dosage forms, drug delivery, and the development of immediate and controlled release dosage forms. Dr. Babu has several years of teaching experience in Pharmaceutical Sciences. He earned his B.S. in Pharmacy (India) and Ph.D. in Pharmaceutics at the University of Connecticut, Storrs, CT.
|
|
Keith S. Ehrlich, C.P.A
|
Vice President, Finance and Administration
Chief Financial Officer
|
Before joining Synta in March 2004, Mr. Ehrlich was Vice President-Finance and Administration and Chief Financial Officer at Argentys Corporation. Previously, Mr. Ehrlich was Vice President-Finance and Administration and Chief Financial Officer at Dyax Corp. and OraVax Inc. (now Acambis) and Director of Finance at Vertex Pharmaceuticals, Inc. He had financial responsibility for the initial public offerings of OraVax and Vertex. Previously, Mr. Ehrlich was a Senior Audit Manager for PricewaterhouseCoopers. Mr. Ehrlich holds a B.A. in Biology from Drew University and an M.B.A. from Rutgers University.
|
|
Rob Kloppenburg
|
Vice President, Investor Relations and Corporate Communications
|
Before joining Synta in November 2006, Mr. Kloppenburg was Senior Vice President and head of the Boston Life Sciences practice of Fleishman-Hillard, Inc., where he provided strategic communications counsel to a variety of clients in the biotechnology and pharmaceutical sectors. Mr. Kloppenburg was Senior Director of Corporate Communications with Millennium Pharmaceuticals from 2001 to 2003, where he was responsible for product and pipeline communications. From 1995 to 2001, Rob Kloppenburg held increasingly senior roles in communications and public affairs at Bayer Corp., first in Canada and later at the North American Pharmaceutical Division headquarters in West Haven, CT. He currently is a member of the Board of Directors of the Institute for Healthcare Communications. Mr. Kloppenburg received his BA in Political Science and Economics from Carleton University in Ottawa, Canada.
|
|
Arthur J. McMahon
|
Vice President, Human Resources
|
Before joining Synta in January 2007, Mr. McMahon served as Senior Director of Human Resources for Cabot Corporation, a publicly traded specialty chemical company. From 1995 to 2001, Mr. McMahon was Vice President of Human Resources for Osprey Systems, Inc., a privately owned software and information technology services company. Mr. McMahon’s past experience in the field of human resources also includes positions with Broadway and Seymour, Inc., Wang Laboratories, Inc. and Raytheon Company. Mr. McMahon earned his B.S. from North Carolina State University and his J.D. from Suffolk University Law School.
|
|
Wendy E. Rieder, Esq.
|
Vice President, Intellectual Property and Legal Affairs
General Counsel
|
Before joining Synta in December 2002, Ms. Rieder served as the co-founder, COO and VP, Business Development and Intellectual Property of Microbiotix, Inc., a privately-held biotechnology company developing small-molecule anti-infectives. She is a registered patent attorney with experience in all aspects of business and intellectual property law relating to private and public companies in the pharmaceutical and biotechnology industries. Ms. Rieder was also the VP, Business Development and Intellectual Property at CereMedix, Inc. and LipoGenics, Inc., a patent attorney at Boehringer Ingelheim Pharmaceuticals, and a patent agent at Fish & Neave. Ms. Rieder holds an M.S. in Organic Chemistry from Columbia University and a J.D. from Fordham University.
|
|
Andrew J. Sonderfan, Ph.D., DABT
|
Vice President, Drug Disposition and Preclinical Safety
|
Before joining Synta in December 2006, Dr. Sonderfan spent five years at Enanta Pharmaceuticals, Inc., during which time he served as Senior Director, Toxicology and Safety Pharmacology. From 2000 to 2001, Dr. Sonderfan was the Director of Toxicology and Product Safety at BioChem Pharma (today, Shire Pharmaceutical Development Inc.). Dr. Sonderfan began his industry career at Syntex, Inc. as Nonclinical Leader, Palonosetron Program. Dr. Sonderfan earned his B.S. in Toxicology from the Philadelphia College of Pharmacy and Science (today, the University of the Sciences in Philadelphia) and his Ph.D. in Toxicology from the University of Kansas Medical Center.
|
|
Lijun Sun, Ph.D.
|
Vice President, Chemistry
|
Dr. Sun joined Shionogi BioReseach in 1997 and was promoted to the positions of Director of Chemistry in 2000 and Senior Director of Chemistry in 2002. He received his Ph.D. in synthetic organic chemistry from Emory University; was post-doctoral fellow in chemistry biology at the Emory University School of Medicine; and has more than 30 issued and pending U.S. patents. Dr. Sun published more than a dozen scientific articles.
|
|
David Noskowitz
|
Senior Director, Regulatory Affairs
|
Before joining Synta in March 2005, Mr. Noskowitz was Director of Regulatory Affairs at Genzyme Corporation, where his efforts contributed to U.S., E.U., and international approvals of Aldurazyme® (laronidase), a treatment for Mucopolysaccharidosis I (MPS I). While at Genzyme, Mr. Noskowitz served as team leader for interdisciplinary project teams and provided regulatory perspective on in-licensing/acquisition due diligence activities. Prior to joining Genzyme in 2000, Mr. Noskowitz was Associate Director and Manager of Regulatory Affairs at Wyeth-Ayerst Research/Genetics Institute, Inc. Prior to that, Mr. Noskowitz served as Regulatory Affairs Manager at Bristol-Myers Squibb. Mr. Noskowitz received an M.Eng. degree in Chemical Engineering from the University of Virginia in Charlottesville, and earned both a B.S. in Environmental Engineering and a B.A. in Chemistry at the University of Rochester.
|
|